Business Context and Reporting Period
Company: SELLAS Life Sciences Group, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 22, 2018
Event: Entry into a Material Definitive Agreement (Warrant Exchange Agreement) with Empery Asset Master Ltd. and related entities.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, or operating margins. It details a specific capital restructuring transaction:
- Debt Issued: Convertible promissory notes with an aggregate principal amount of $64,403.12.
- Interest Rate: 4.75% per annum (increases to 18% per annum upon an event of default).
- Maturity Date: August 22, 2018.
- Conversion Price: $7.00 per share (subject to adjustments).
- Conversion Restriction: Holder cannot convert if it would beneficially own more than 9.99% of outstanding Common Stock.
- Warrants Surrendered: Warrants to purchase 26,668 shares of Common Stock (post-reverse split basis).
Material Changes
The Company exchanged outstanding warrants held by Empery for new convertible debt. This transaction alters the Company's capital structure by replacing equity warrants with a direct financial obligation (notes payable). The filing does not provide comparative financial data against prior periods as it is a transaction-specific report.
Outlook, Risks, and Contingencies
- Default Provisions: An "event of default" triggers a penalty interest rate of 18% and allows conversion at a discounted price (70% of the lowest VWAP over the prior 10 trading days). Default events include suspension of trading for 5 days, failure to deliver shares, failure to pay, bankruptcy, or uncured breaches of covenants.
- Most Favored Nation Clause: If the Company offers more favorable terms to other warrant holders, Empery is entitled to those terms unless they elect otherwise within 10 trading days.
- Regulatory Status: The issuance of notes relied on Section 3(a)(9) of the Securities Act of 1933 (unregistered sale).
- Documentation: Full text of the agreement will be filed in the Annual Report on Form 10-K for the year ended December 31, 2017.
Investor Verification Checklist
- Verify the total outstanding debt load of the Company to assess the impact of the new $64,403.12 obligation.
- Confirm the current trading volume and price of Common Stock to evaluate the risk of the 9.99% beneficial ownership cap limiting conversion.
- Monitor for any future warrant exchange agreements with other holders that could trigger the "most favored nation" clause for Empery.
- Review the upcoming Form 10-K for the full text of the Warrant Exchange Agreement and Empery Notes.